Azenta shares jump on Q4 results, buyback plans
Shares of Azenta Inc. (AZTA) jumped 11.9% after hours on Monday after the life-sciences company reported fourth-quarter results that beat expectations and announced plans to buy back an extra $500 million in stock in fiscal 2024. The company -- whose products and services help researchers store, handle and process chemical and biological samples -- reported net income of $3.4 million, or 6 cents a share, compared with a loss of $20.8 million, or 28 cents a share, in the same quarter last year. Revenue rose 25% to $172.4 million, compared with $137.6 million in the prior-year quarter. Adjusted earnings per share were 13 cents. Analysts polled by FactSet expected adjusted earnings of 2 cents a share on sales of $163.9 million. Azenta said it expected full fiscal 2024 adjusted earnings per share of 19 cents to 29 cents, compared with FactSet forecasts for 24 cents.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-13-23 1701ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?